Article Information
History
- December 14, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Joyce E.M. van der Heijden1,
- Violette Gijsen1,
- Anne M. van Uden1,
- Marika de Hoop-Sommen1,
- Jolien J.M. Freriksen1,
- Elke Jacobs2,
- Rick Greupink1 and
- Saskia N. de Wildt1,3,4,*
- 1Department of Pharmacy - Pharmacology Toxicology, Radboud university medical center, Nijmegen, The Netherlands
- 2HagaZiekenhuis-Juliana Childrens Hospital
- 3Department of Neonatal and Pediatric Intensive Care, Division of Pediatric Intensive care, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands
- 4Department of Intensive Care, Radboud university medical center, Nijmegen, The Netherlands
- ↵*Corresponding author – Prof. dr. Saskia N. de Wildt, Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud university medical center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands; Saskia.deWildt{at}radboudumc.nl.
Posted December 14, 2024.
Pragmatic modeling supports current dosing guidelines for carbamazepine and valproic acid for the treatment of epilepsy in children
